The Board intends to effect the Bonus Share Issue to double the amount of the Company’s issued share capital. Each Shareholder will receive one new Ordinary Share for every one existing Ordinary Share (or ADS as the case may be) held on the Record Date. The Board believes that the Bonus Share Issue will increase the liquidity and marketability of the stock. The proposal will not affect Shareholders underlying interests and their entitlements to the earnings and net assets of the Company.
The Notice of the AGM and Form of Proxy together with the Company’s Annual Report for 2007 are being posted to shareholders on Tuesday June 17, 2008. A copy of the Annual Report, Notice of the AGM and Form of Proxy are also being submitted to the Irish Stock Exchange and will shortly be available for inspection at the:
Company Announcements Office,
Irish Stock Exchange,
28 Anglesea Street,
Dublin 2,
Ireland
(Telephone number +353 1 6174200)
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON teams have successfully conducted over 1,900 development projects and over 2,300 consultancy engagements across all major therapeutic areas. ICON currently has approximately 6,150 employees, operating from 69 locations in 36 countries. Further information is available at www.iconplc.com
Source: ICON plc
Enquiries:
Investor Relations 1-888-381-7923 or
Ciaran Murray CFO + 353 –1-291-2000
Both at ICON.